Trials / Completed
CompletedNCT05564117
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
Efficacy and Safety of Oral Semaglutide 25 mg Once Daily in Adults With Overweight or Obesity
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 307 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily. This study will last for 72 weeks, which includes 1-week screening period, 64 weeks of treatment period and 7 weeks of follow up period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Semaglutide | Semaglutide tablets orally once daily for 64 weeks. |
| DRUG | Placebo semaglutide | Semaglutide placebo-matching tablets orally once daily for 64 weeks. |
Timeline
- Start date
- 2022-10-11
- Primary completion
- 2024-04-18
- Completion
- 2024-05-07
- First posted
- 2022-10-03
- Last updated
- 2026-02-25
- Results posted
- 2026-02-25
Locations
23 sites across 4 countries: United States, Canada, Germany, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05564117. Inclusion in this directory is not an endorsement.